175
Views
4
CrossRef citations to date
0
Altmetric
Articles

A randomized split-face clinical trial of conventional vs indoor-daylight photodynamic therapy for the treatment of multiple actinic keratosis of the face and scalp and photoaging

, , , , , , , & show all
Pages 2250-2256 | Received 28 May 2021, Accepted 06 Jun 2021, Published online: 28 Jun 2021

References

  • Calzavara-Pinton P, Haedersdal M, Barber K, et al. Structured expert consensus on actinic keratosis: treatment algorithm focusing on daylight PDT. J Cutan Med Surg. 2017;21(1_suppl):3S–16S.
  • Fernández-Figueras MT, Carrato C, Sáenz X, et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29(5):991–997.
  • Morton CA, Szeimies RM, Basset-Séguin N, et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2: emerging indications – field cancerization, photorejuvenation and inflammatory/infective dermatoses. J Eur Acad Dermatol Venereol. 2020;34(1):17–29.
  • Calzavara-Pinton PG, Venturini M, Sala R. Photodynamic therapy: update 2006. Part 1: photochemistry and photobiology. J Eur Acad Dermatol Venerol. 2007;21(3):293–302.
  • Moggio E, Arisi M, Zane C, et al. A randomized split-face clinical trial analyzing daylight photodynamic therapy with methyl aminolaevulinate vs ingenol mebutate gel for the treatment of multiple actinic keratoses of the face and the scalp. Photodiagnosis Photodyn Ther. 2016;16:161–165.
  • Szeimïes RM. Pain perception during photodynamic therapy: why is daylight PDT with methyl aminolevulinate almost pain-free? A review on the underlying mechanisms, clinical reflections and resulting opportunities. G Ital Dermatol Venereol. 2018;153(6):793–799.
  • Wiegell SR, Haedersdal M, Eriksen P, et al. Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. Br J Dermatol. 2009;160(6):1308–1314.
  • Morton CA, Wulf HC, Szeimies RM, et al. Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus. J Eur Acad Dermatol Venereol. 2015;29(9):1718–1723.
  • Wiegell SR, Fabricius S, Heydenreich J, et al. Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations. Br J Dermatol. 2013;168(1):186–191.
  • Lerche CM, Heerfordt IM, Heydenreich J, et al. Alternatives to outdoor daylight illumination for photodynamic therapy–use of greenhouses and artificial light sources. Int J Mol Sci. 2016;17(3):309.
  • Mordon S, Vignion-Dewalle AS, Thecua E, et al. Can daylight-PDT be performed indoor? G Ital Dermatol Venereol. 2018;153(6):811–816.
  • Kellner C, Bauriedl S, Hollstein S, et al. Simulated-daylight photodynamic therapy with BF-200 aminolaevulinic acid for actinic keratosis: assessment of the efficacy and tolerability in a retrospective study. Br J Dermatol. 2015;172(4):1146–1148.
  • Wiegell SR, Heydenreich J, Fabricius S, et al. Continuous ultra-low-intensity artificial daylight is not as effective as red LED light in photodynamic therapy of multiple actinic keratoses. Photodermatol Photoimmunol Photomed. 2011;27(6):280–285.
  • Prahl S. Protoporphyrin IX dimethyl ester. 2014. [cited 2020 Apr 25]. Available at: http://omlc.ogi.edu/spectra/PhotochemCAD/html/149.html.
  • Galderma (U.K) Ltd. Metvix 160 mg/g cream: summary of product characteristics. 2021. [cited 2021 Apr 23]. Available at: https://www.medicines.org.uk/emc/medicine/11913.
  • Arisi M, Zane C, Polonioli M, et al. Effects of MAL-PDT, ingenol mebutate and diclofenac plus hyaluronate gel monitored by high-frequency ultrasound and digital dermoscopy in actinic keratosis – a randomized trial. J Eur Acad Dermatol Venereol. 2020;34(6):1225–1232.
  • Zane C, Facchinetti E, Rossi MT, et al. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. Br J Dermatol. 2014;170(5):1143–1150.
  • Babilas P, Kohl E, Maisch T, et al. In vitro and in vivo comparison of two different light sources for topical photodynamic therapy. Br J Dermatol. 2006;154(4):712–718.
  • Zane C, Capezzera R, Sala R, et al. Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. Lasers Surg Med. 2007;39(3):203–209.
  • Dover JS, Bhatia AC, Stewart B, et al. Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. Arch Dermatol. 2005;141(10):1247–1252.
  • Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol. 2002;47(2):258–262.
  • Zane C, Fabiano A, Arisi M, et al. A randomized split-face clinical trial of photodynamic therapy with methyl aminolevulinate versus ingenol mebutate gel for the treatment of multiple actinic keratoses of the face and scalp. Dermatology. 2016;232(4):472–477.
  • O’Gorman SM, Clowry J, Manley M, et al. Artificial white light vs daylight photodynamic therapy for actinic keratoses: a randomized clinical trial. JAMA Dermatol. 2016;152(6):638–644.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.